Global Antibiotic Resistance Partnership

  • Symposium: "Antibiotic Resistance: National Actions Contribute to a Global Solution"

    Health ministry representatives, GARP working group members and scientific experts from India, Kenya, Nepal, Mozambique and South Africa spoke at on March 3 the International Congress for Infectious Diseases (ICID) in Hyderabad, India about their countries’ journeys toward national action plans to curb antibiotic resistance. The symposium was chaired by Ramanan Laxminarayan, CDDEP, and Chand Wattal of Sir Ganga Ram Hospital in Delhi. 

  • GARP-Mozambique Situation Analysis Launch

    The GARP-Mozambique Working Group has launched its Situation Analysis and Recommendations on Antibiotic Use and Resistance in Mozambique. The report, which is now available on the CDDEP website in both English and Portuguese, was launched by the working group at a meeting in Maputo. The report culminates in a series of recommendations for combating antibiotic resistance in the country, laying the groundwork for development of a national action plan, as called for by the World Health Organization in its Global Action Plan for Antimicrobial Resistance.

  • GARPNet News: Vol 2 Issue 3

    The May issue of GARPNet News, the newsletter of the Global Antibiotic Resistance Partnership, is now available online. The issue features a summary of a recent Wellcome Trust summit on integrating science and policy for action on antimicrobial resistance, held in London April 26-27. Sign up to receive the bi-monthly newsletter on global antibiotic resistance and GARP projects here.

  • GARP-Vietnam Secretariat Signs Aide Memoire with Vietnamese Government

    The Oxford University Clinical Research Unit (OUCRU) in Hanoi, secretariat of the GARP-Vietnam working group, signed an Aide Memoire on antibiotic resistance with the Vietnamese Government. The Ministries of Health, Agriculture and Rural Development, Industry and Trade, Natural Resources and Environment joined other development partners in recognizing the growing global threat of antibiotic resistance and committing to take steps to control it.

  • GARP Members attend WHO Regional Expert's Meeting

    GARP working group members from Kenya, Tanzania and South Africa attended the WHO Regional Office for Africa’s Consultative Expert’s Meeting in Brazzaville, Congo to discuss means of combating antimicrobial resistance. They were invited because of their GARP connection, and are among the few African countries with data on antibiotic resistance to share. This event preceded the World Health Assembly, where member states approved the Global Action Plan on Antimicrobial resistance, which calls on all countries to develop and implement national AMR plans within 2 years.

GARP Phase 3

GARP entered its third phase in November 2015. Phase three will see the expansion of the current GARP network consolidated around two hubs, in South and South East Asia and in East and South Africa. Current GARP countries will act as mentors for new members, with collaboration between researchers and policy makers across the network. CDDEP will continue to provide guidance, tools and technical support to ensure that the partnership continues to grow.  

About GARP

The Global Antibiotic Resistance Partnership (GARP) is a project of the Center for Disease Dynamics, Economics & Policy (CDDEP) that has established local policy analysis and policy development capacity related to antibiotic resistance in selected low- and middle-income countries. With support from the Bill & Melinda Gates Foundation, GARP has supported the creation of multi-sectoral national-level working groups whose mandate is to understand and document antibiotic use and antibiotic resistance in the human and animal population in the national context, and to then develop evidence-based proposals to encourage the introduction of measures to preserve antibiotic effectiveness, slow the spread of antibiotic resistance and improve antibiotic access. More than just establishing this capacity in eight diverse countries, CDDEP has developed a modus operandi for establishing a local capacity for antibiotic policy that is not duplicated by any other program, recognizing that country strengths and situations will take them in somewhat different directions.